No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)
Clinical trials for patients whose PSA rises while they are on androgen deprivation therapy but prostate cancer has not metastasized. (Stage 4)
Find Your Trial
Low Risk
Intermediate Risk
High Risk
Cancer Recurrence
Non-Metastatic Castration Resistant
Metastatic Castration Sensitive
Metastatic Castration Resistant
Promise Registry - All Risk Levels
PROMISE is a nationwide registry of prostate cancer patients with inherited mutations by screening approximately 5,000 participants with a prostate cancer diagnosis. The PROMISE team is studying how these mutations affect patient outcomes.
This information is for educational purposes only and not intended as medical advice.
Patients should consult their medical doctor for advice and recommendations about specific clinical trials.